<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) November 15, 1999
-----------------
BOSTON LIFE SCIENCES, INC.
-----------------------------------------------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
- ------------------------------------------ ----------- ------------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) File No.)
137 Newbury Street
8th Floor
Boston, Massachusetts 02116
- ------------------------------------------ ----------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
-----------------
<PAGE>
Item 5. Other Events.
-------------
On November 15, 1999, the Company announced that Jesup & Lamont Securities, a
New York-based brokerage and investment banking firm, had initiated research
coverage of the company with a strong buy rating.
Jesup & Lamont is a full service brokerage and investment banking firm providing
institutional sales and trading services, equity research, asset management for
select clientele, and financial advisory services in connection with mergers and
acquisitions, capital market transactions, restructurings and other corporate
finance matters. The firm also initiates merchant banking transactions and
manages a portfolio of its own principal investments.
On November 22, 1999, the Company announced that Aurora Capital, a New York-
based brokerage and investment banking firm, had updated their research coverage
of the Company with a buy rating.
Aurora Capital is a full service brokerage and investment banking firm dedicated
to serving life sciences companies and providing valuable investment
opportunities to its clients. The firm also maintains strong relationships with
a number of pharmaceutical and biotechnology companies and institutional
investors.
On November 23, 1999, the Company announced that it has recently submitted its
proposed Phase II study to the FDA for the use of the Company's radio-imaging
agent, Altropane, to diagnose ADHD. The proposed study, to be performed under
the Company's current IND, is designed to demonstrate that children with
expertly-diagnosed ADHD have significantly elevated Dopamine Transporter (DAT)
levels (measured using Altropane-SPECT scans) compared to either clinically
normal children or those with other behavioral abnormalities. The Company plans
to meet with the FDA to discuss and finalize the details of the protocol in mid-
December, and hopes to initiate the Phase II study in January or February 2000.
The Company previously announced the results of a study performed in adults with
long-standing ADHD, which demonstrated for the first time that ADHD was
associated with an abnormal elevation in DAT levels compared to age-matched
normal individuals. The detailed results of this study have been accepted for
publication by a leading peer-reviewed medical journal.
Altropane is currently in Phase III testing for the early diagnosis of
Parkinson's Disease. The Company hopes to complete this Phase III study and to
file for marketing approval for the PD indication in the first quarter of 2000.
The Company believes that the combined market potential for both the ADHD and
Parkinson's Disease diagnostic indications could be almost $500 million per year
in the U.S., making Altropane, if approved, the potential to become the highest
revenue-generating radiopharmaceutical ever.
Item 7. Exhibits.
---------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated November 15, 1999.
99.2 Press Release, dated November 22, 1999.
99.3 Press Release, dated November 23, 1999.
1
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: November 29, 1999 By: /s/Joseph Hernon
-------------------------
Joseph Hernon
Chief Financial Officer
2
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit No. Pages
----------- -----
<C> <S> <C>
99.1 Press Release, dated November 15, 1999 4
99.2 Press Release, dated November 22, 1999 5
99.3 Press Release, dated November 23, 1999 6
</TABLE>
3
<PAGE>
Exhibit 99.1
CONTACTS:
Media Analyst Boston Life Sciences, Inc.
Jim Weinrebe or Lloyd Benson Neil Berkman David Hillson
Schwartz Communications Berkman Associates Chief Executive Officer
781.684.0770 310.277.5162 617.425.0200
JESUP & LAMONT SECURITIES INITIATES COVERAGE OF
BOSTON LIFE SCIENCES, INC. WITH A RATING OF STRONG BUY
November 15, 1999, Boston, Mass.--Boston Life Sciences, Inc. (NASDAQ: BLSI) a
biotechnology company, announced that Jesup & Lamont Securities, a New York-
based brokerage and investment banking firm, has initiated research coverage of
the company with a strong buy rating.
Jesup & Lamont is a full service brokerage and investment banking firm providing
institutional sales and trading services, equity research, asset management for
select clientele, and financial advisory services in connection with mergers and
acquisitions, capital market transactions, restructurings and other corporate
finance matters. The firm also initiates merchant banking transactions and
manages a portfolio of its own principal investments.
Boston Life Sciences, Inc. is developing novel treatments for cancer, autoimmune
disease, and central nervous system disorders. Products awaiting FDA review, in
clinical trials or in preclinical development by BLSI include: Altropane(TM), a
radioimaging agent for the early diagnosis of Parkinson's Disease and Attention
Deficit Hyperactivity Disorder; Troponin I as an anti-angiogenic treatment for
cancer; AF-1 and Inosine for the potential treatment of stroke and spinal cord
injury; Therafectin(R) for the treatment of rheumatoid arthritis; and
transcription factors that may control expression of molecules associated with
autoimmune disease and allergies.
# # #
4
<PAGE>
EXHIBIT 99.2
AURORA CAPITAL UPDATES COVERAGE OF
BOSTON LIFE SCIENCES, INC. WITH A BUY RATING
November 22, 1999, Boston, Mass.--Boston Life Sciences, Inc. (NASDAQ: BLSI) a
biotechnology company, announced that Aurora Capital, a New York-based brokerage
and investment banking firm, has updated their research coverage of the Company
with a buy rating.
Aurora Capital is a full service brokerage and investment banking firm dedicated
to serving life sciences companies and providing valuable investment
opportunities to its clients. The firm also maintains strong relationships with
a number of pharmaceutical and biotechnology companies and institutional
investors.
Boston Life Sciences, Inc. is developing novel treatments for cancer, autoimmune
disease, and central nervous system disorders. Products awaiting FDA review, in
clinical trials or in preclinical development by BLSI include: Altropane(TM), a
radioimaging agent for the early diagnosis of Parkinson's Disease and Attention
Deficit Hyperactivity Disorder; Troponin I as an anti-angiogenic treatment for
cancer; AF-1 and Inosine for the potential treatment of stroke and spinal cord
injury; Therafectin(R) for the treatment of rheumatoid arthritis; and
transcription factors that may control expression of molecules associated with
autoimmune disease and allergies.
For additional information, please contact:
Boston Life Sciences, Inc.
David Hillson
Chief Executive Officer
617.425.0200
Media
Jim Weinrebe
Schwartz Communications
781.684.0770
5
<PAGE>
EXHIBIT 99.3
BOSTON LIFE SCIENCES SUBMITS PHASE II PROTOCOL FOR THE DIAGNOSIS OF
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) USING ALTROPANE
November 23, 1999--Boston, MA--Boston Life Sciences, Inc. (NASDAQ: BLSI)
announced that the Company has recently submitted its proposed Phase II study to
the FDA for the use of the Company's radio-imaging agent, Altropane, to diagnose
ADHD. The proposed study, to be performed under the Company's current IND is
designed to demonstrate that children with expertly-diagnosed ADHD have
significantly elevated Dopamine Transporter (DAT) levels (measured using
Altropane-SPECT scans) compared to either clinically normal children or those
with other behavioral abnormalities. The Company plans to meet with the FDA to
discuss and finalize the details of the protocol in mid-December, and hopes to
initiate the Phase II study in January or February 2000.
The Company previously announced the results of a study performed in adults with
long-standing ADHD, which demonstrated for the first time that ADHD was
associated with an abnormal elevation in DAT levels compared to age-matched
normal individuals. The detailed results of this study have been accepted for
publication by a leading peer-reviewed medical journal.
Dr. Edward Hallowell, nationally-recognized expert in treating ADHD, and author
of the book Driven to Distraction stated, "Altropane is the most promising
development I've seen in a long time in terms of our coming up with an actual
physical test that could help us pin down the diagnosis of ADHD."
Altropane is currently in Phase III testing for the early diagnosis of
Parkinson's Disease. The Company hopes to complete this Phase III study and to
file for marketing approval for the PD indication in the first quarter of 2000.
The Company believes that the combined market potential for both the ADHD and
Parkinson's Disease diagnostic indications could be almost $500 million per year
in the U.S., making Altropane, if approved, the potential to become the highest
revenue-generating radiopharmaceutical ever.
BLSI is developing novel treatments for cancer, autoimmune diseases, and central
nervous system disorders. In addition to Altropane(TM), BLSI's products
awaiting FDA review, in clinical trials or in preclinical development include
Therafectin(R), an oral drug for the treatment of Rheumatoid Arthritis; Troponin
I, a naturally-occurring anti-angiogenesis factor for the treatment of solid
tumors; and AF-1 and Inosine, nerve growth factors for the treatment of acute
and chronic CNS disorders.
Statements made in this press release other than statements of historical fact
represent forward-looking statements. Such statements include, without
limitation, statements regarding expectations or beliefs as to future results or
events, such as the expected timing and results of clinical trials, schedules of
IND, NDA, and other regulatory submissions, the timing of product introductions,
the market size for the Company's products and possible advantages of the
Company's products. All such forward-looking statements involve substantial
risks and uncertainties and actual results may vary materially from these
statements. Factors that may affect future results include: results of
scientific data from clinical trials; delays in the regulatory or development
processes; the ability to obtain intellectual property protection, the
availability of financing, market acceptance of the Company's products and other
possible risks and uncertainties that have been noted in reports filed by the
Company with the Securities and Exchange Commission, including the Company's
Annual Report on Form 10-K/A.
For additional information, please contact:
Corporate Investor Media
Marc Lanser Maria Zapf Jim Weinrebe
Chief Scientific Officer Investor Relations Schwartz Communications
617.425.0200 617.425.0200 781.684.0770
6
